Arthritis Research & Therapy

Table 2 Serological characteristics of rheumatoid arthirits patients prior to and following rituximab treatment

From: Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis

	Bone marrow			Peripheral blood
	Baseline	1 month	3 months	Baseline	3 months
WBC, 10 ⁶ /ml	20.5 ± 12.6	17.5 ± 6.5	24.2 ± 15.9	6.8 ± 3.0	7.1 ± 3.2
CD19+, %	5.6 ± 3.7	1.1 ± 0.9**	1.6 ± 1.3**	12.2 ± 6.4	0***
CD3+, %	28.3 ± 12.7	36.2 ± 14.3	22.7 ± 6.2	46.9 ± 16.2	42.8 ± 13.9
CD138+, %	0.83 ± 0.56	0.70 ± 0.47	0.73 ± 0.51	-	-
ELISPOT, 10 ⁶ lymphocytes/ml
IgG	11073 ± 11363	10574 ± 8414	7703 ± 7451	1504 ± 3383	427 ± 800
IgM	8163 ± 8448	5922 ± 5492**	4058 ± 6833	2013 ± 7070	123 ± 223
IgA	6009 ± 4628	7010 ± 6345	5122 ± 4015	1280 ± 2743	471 ± 1094
RF, U/ml
IgG	Not assessed	Not assessed	Not assessed	50 ± 31	34 ± 26***
IgM	Not assessed	Not assessed	Not assessed	78 ± 31	64 ± 49**
IgA	Not assessed	Not assessed	Not assessed	37 ± 28	30 ± 25**
Total Igs, mg/L
IgG	Not assessed	Not assessed	Not assessed	13 ± 4.5	12.3 ± 4.2***
IgM	Not assessed	Not assessed	Not assessed	1.9 ± 1.2	1.6 ± 1.1**
IgA	Not assessed	Not assessed	Not assessed	3.6 ± 1.8	3.0 ± 1.3

* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001.
Values are given as mean ± standard deviation.
Ig = immunoglobulin; RF = rheumatoid factor; WBC = white blood cell.

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com